ПНЕВМОНИЯ У БОЛЬНЫХ ХОБЛ, ПОЛУЧАЮЩИХ ИНГАЛЯЦИОННЫЕ ГЛЮКОКОРТИКОСТЕРОИДЫ

Скачать статью в PDF
Номер журнала: 
2
Год издания: 
2017

А. Визель, доктор медицинских наук, профессор, И. Визель, кандидат медицинских наук, Э. Гизатуллина, кандидат медицинских наук Казанский государственный медицинский университет E-mail: lordara@inbox.ru

Обзор посвящен оценке безопасности применения ингаляционных глюкокортикостероидов и их сочетаний с β2-адреномиметиками длительного действия при хронической обструктивной болезни легких.
Ключевые слова: 
пульмонология
хроническая обструктивная болезнь легких
пневмония
ингаляционные глюкокортикостероиды
Для цитирования
Визель А., Визель И., Гизатуллина Э. ПНЕВМОНИЯ У БОЛЬНЫХ ХОБЛ, ПОЛУЧАЮЩИХ ИНГАЛЯЦИОННЫЕ ГЛЮКОКОРТИКОСТЕРОИДЫ . Врач, 2017; (2): 17-23

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Barnes P. Corticosteroid effects on cell signaling // Eur. Respir. J. – 2006; 27 (2): 413–26.
  2. Crim C., Pierre L., Daley-Yates P. A review of the pharmacology and pharmacokinetics of inhaled adults with asthma // Cochrane Database Syst. Rev. – 2000; CD001117.
  3. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2016. Available at: http://www.ginasthma.org/
  4. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available at: http://www.goldcopd.org/
  5. Sibila O., Anzueto A., Restrepo M.I. The paradoxical effect on pneumonia of chronic inhaled corticosteroids // Clin. Pulm. Med. – 2013; 20 (1): 1–14.
  6. Nannini L., Poole P., Milan S. et al. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease // Cochrane Database Syst Rev. – 2013; 11: CD003794.
  7. Kaplan A. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice // Int. J. Chron. Obstruct. Pulmon. Dis. – 2015; 10: 2535–48.
  8. Kruis A., Ställberg B., Jones R. et al. Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study // PLoS One. – 2014; 9 (3): e90145.
  9. Niederseer D., Richter S., Neunhäuserer D. et al. Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study // Sleep Breath. – 2015; 19 (3): 801–8.
  10. Wilkie M., Finch S., Schembri S. Inhaled corticosteroids for chronic obstructive pulmonary disease – the shifting treatment paradigm // COPD. – 2015; 12 (5): 582–90.
  11. Price D., Miravitlles M., Pavord I. et al. First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis // NPJ Prim. Care Respir. Med. – 2016; 26: 16061.
  12. Барабанова Е.Н., Колонтарева Ю.М. Ингаляционные глюкокортикостероиды / длительно действующие β2-агонисты в лечении хронической обструктивной болезни легких: дискуссия продолжается // Пульмонология. – 2016; 26 (3): 357–63.
  13. Singanayagam A., Chalmers J., Hill A. Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association // QJM. – 2010; 103 (6): 379–85.
  14. Calverley P., Anderson J., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease // N. Engl. J. Med. – 2007; 356 (8): 775–89.
  15. Ernst P., Gonzalez A., Brassard P. et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia // Am. J. Respir. Crit Care. Med. – 2007; 176 (2): 162–6.
  16. Ernst P., Suissa S. Pneumonia in elderly patients with chronic obstructive pulmonary disease // Curr. Infect. Dis. Rep. – 2008; 10 (3): 223–8.
  17. Баймаканова Г.Е., Зубаирова П.А., Авдеев С.Н. и др. Особенности клинической картины и течения внебольничной пневмонии у пациентов с хронической обструктивной болезнью легких // Пульмонология. – 2009; 2: 33–41.
  18. Calverley P., Stockley R., Seemungal T. et al. Reported pneumonia in COPD: findings from the INSPIRE study // Chest. – 2011; 139 (3): 505–12.
  19. Yawn B., Li Y., Tian H. et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis // Int. J. Chron. Obstruct. Pulmon. Dis. – 2013; 8: 295–304.
  20. Sibila O., Laserna E., Mortensen E. et al. Effects of inhaled corticosteroids on pneumonia severity and antimicrobial resistance // Respir. Care. – 2013; 58 (9): 1489–94.
  21. Wedzicha J., Singh D., Vestbo J. et al. Extrafine beclomethasone / formoterol in severe COPD patients with history of exacerbations // Respir. Med. – 2014; 108 (8): 1153–62.
  22. Crim C., Dransfield M., Bourbeau J. et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD // Ann. Am. Thorac. Soc. – 2015; 12 (1): 27–34.
  23. Halpin D., Gray J., Edwards S. et al. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials // Int. J. Clin. Pract. – 2011; 65 (7): 764–74.
  24. Ruiz García V., Compte Torrero L. Risk of pneumonia with inhaled corticosteroids for stable chronic obstructive pulmonary disease patients // Med. Clin. (Barc). – 2011; 137 (7): 302–4.
  25. Janson C., Larsson K., Lisspers K. et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS) // BMJ. – 2013; 346: f3306.
  26. Roggeri A., Micheletto C., Roggeri D. Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study // Int. J. Chron. Obstruct. Pulmon. Dis. – 2014; 9: 569–76.
  27. Suissa S., Patenaude V., Lapi F. et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia // Thorax. – 2013; 68 (11): 1029–36.
  28. Latorre M., Novelli F., Vagaggini B. et al. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS // Pulm. Pharmacol. Ther. – 2015; 30: 44–50.
  29. Kern D., Davis J., Williams S. et al. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study // Respir. Res. – 2015; 16: 52.
  30. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Inhaled_corticosteroids_for_chronic_obstructive_pulmonary_disease/human_referral_prac_000050.jsp&mid=WC0b01ac05805c516f (27.01.2017)
  31. O'Byrne P., Pedersen S., Carlsson L. et al. Risks of pneumonia in asthmatic patients taking inhaled corticosteroids // Am. J. Respir. Crit. Care Med. – 2011; 183 (5): 589–895.
  32. Mapel D., Schum M., Yood M. et al. Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators // Prim. Care. Respir. J. – 2010; 19 (2): 109–17.
  33. Marzoratti L., Iannella H., Waterer G. Inhaled corticosteroids and the increased risk of pneumonia // Ther. Adv. Respi. Dis. – 2013; 7 (4): 225–34.
  34. Festic E., Bansal V., Gajic O. et al. Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study // Mayo Clin. Proc. – 2014; 89 (2): 154–62.
  35. Yamanashi K., Marumo S., Shoji T. et al. The relationship between perioperative administration of inhaled corticosteroid and postoperative respiratory complications after pulmonary resection for non-small-cell lung cancer in patients with chronic obstructive pulmonary disease // Gen. Thorac. Cardiovasc. Surg. – 2015; 63 (12): 652–9.
  36. Ernst P., Coulombe J., Brassard P. et al. The risk of sepsis with inhaled and oral corticosteroids in patients with COPD // COPD. – 2016; 1–6. DOI: 10.1080/15412555.2016.1238450. Epub ahead of print.
  37. Vestbo J., Leather D., Diar Bakerly N. et al. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice // N. Engl. J. Med. – 2016; 375 (13): 1253–60.
  38. Malo de Molina R., Mortensen E., Restrepo M. et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia // Eur. Respir. J. – 2010; 36 (4): 751–7.
  39. Chen D., Restrepo M., Fine M. et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia // Am. J. Respir. Crit. Care Med. – 2011; 184 (3): 312–6.
  40. Mangi A., Bansal V., Li G. et al. Pre-hospital use of inhaled corticosteroids and inhaled beta agonists and incidence of ARDS: A population-based study // Acta Med. Acad. – 2015; 44 (2): 109–16.
  41. Sellares J., López-Giraldo A., Lucena C. et al. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia // Am. J. Respir. Crit. Care. Med. – 2013; 187 (11): 1241–8.
  42. Festic E., Scanlon P. Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? // Am. J. Respir. Crit. Care. Med. – 2015; 191 (2): 141–8.
  43. Papi A., Jones P., Dalvi P. et al. The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD // Int. J. Chron. Obstruct. Pulmon. Dis. – 2015; 10: 2431–8.